Absence of Inhibitors in Previously Untreated Patients with Severe Haemophilia A after Exposure to a Single Intermediate Purity Factor VIII Product

Summary

Use of high purity and recombinant factor VIII (FVIII) concentrates has been thought to be associated with an increased incidence of FVIII inhibitors in patients with severe haemophilia A. Comparison with comparable historical control groups has suggested that the true incidence of inhibitors in patients with severe haemophilia A was ~20-25%, similar to the incidence seen with new high purity and recombinant FVIII products.

We have conducted a study of inhibitor development in a cohort of 37 boys with severe haemophilia A (VIII: C <2 u/dl) exposed only to a single FVIII concentrate (BPL 8Y) with no previous blood or blood product exposure. This factor VIII concentrate is an intermediate purity product with a specific activity of ~2 IU/mg protein and contains well preserved von Willebrand factor multimers. It is manufactured by conventional fractionation technologies and terminally dry heat treated at 80° C for 72 h.

• References

• 1 Kasper CK. Incidence and course of inhibitors among patients with classic haemophilia. Thromb Diath Haemorrh 1973; 30: 263-271
• 2 Lusher JM, Arkin S, Abildgaard CF. Schwartz RS and Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated with haemophilia A. N Engl J Med 1993; 328: 453-459
• 3 Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White IIIG, Lee M. Recombinate Study Group. A multicenter study of recombinant factor VIII (Recombinate): safety, effucacy and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994; 83: 2428-2435
• 4 Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher J, Glader B, Aledort L. Frequency of inhibitor development in haemophiliacs treated with low purity factor VIII. Lancet 1993; 342: 462-464
• 5 de BiasiR, Rocino A, Papa ML, Salerno E, Mastrullo L, De BlasiD. Incidence of factor VIII inhibitor development in haemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost 1994; 71 (05) 544-547
• 6 McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. Haemophilia Study Group. The natural history of factor VIII :C inhibitors in patients with haemophilia A: A national cooperative study II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71: 344-348
• 7 Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungor T, Krackhardt B, Komhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-598
• 8 Tuddenham EGD, Cooper DN, Gitschier J, Higuchi M, Hoyer LW, Yoshioka A, Peake JR, Schwaab R, Olek K, Kazazian HH, Lavergene JM, Giannelli F, Antonarakis SE. Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIH gene. Nucl Acids Res 1991; 19: 4821-4833
• 9 Peerlinck K, Rosendaal FR, Vermylen J. Incidence of inhibitor development in a group of young haemophilia A patients treated exclusively with lyophilized cryoprecipitate. Blood 1993; 81: 3332-3335
• 10 Lawrie AS, Harrison P, Armstrong AL, Wilboum BR, Dalton RG, Savidge GF. Comparison of the in vitro characteristics of vin Willebrand factor in British and commercial factor VIII concentrates. Brit J Haematol 1989; 73: 100-104
• 11 Bemtorp E, Ekman M, Gunnarsson M, Nilsson IM. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations. Haemophilia 1996; 02: 95-99
• 12 Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 1996; 76: 749-754
• 13 Colvin BT, Hay CRM, Hill FGH, Preston FE. The incidence of factor VIII inhibitors in the United Kingdom, 1990-1993. Brit J Haematol 1995; 89: 908-910